Patricia Pilar Chaves-Guerrero

Dr. Patricia Pilar Chaves-Guerrero

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, Málaga, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
PCPatricia Pilar Chaves-Guerrero
Patricia Pilar Chaves-Guerrero
MGMaría Garrido
María Garrido
JOJavier Oliver
Javier Oliver
EPElisabeth Perez-Ruiz
Elisabeth Perez-Ruiz
Isabel BarraganIsabel Barragan
Isabel Barragan
ARAntonio Rueda-Domínguez
Antonio Rueda-Domínguez
Head and neck cancer is the sixth most frequent cancer type. Drug resistance and toxicity are common challenges of the existing therapies, making the development of reliable preclinical models essential for the study of the involved molecular mechanisms as well as for eventual intervention approaches that improve the clinical outcome. Preclinical models of head and neck squamous cell carcinoma have been traditionally based on cell lines and murine models. In this review, we will go over the most frequently used preclinical models, from immortalised-cell and primary tumour cultures in monolayer or 3D, to the currently available animal models. We will scrutinise their efficiency in mimicking the molecular and cellular complexity of head and neck squamous cell carcinoma. Finally, the challenges and the opportunities of other envisaged putative approaches, as well as the potential of the preclinical models to further develop personalised therapies will be discussed.

25 April 2008 in Allergy
Verified
Journal Article
Closed access
PDF file
Tahia FernandezTahia Fernandez
Tahia Fernandez
CMCristobalina Mayorga
Cristobalina Mayorga
MTMaría J Torres
María J Torres
JCJosé Antonio Cornejo-García
José Antonio Cornejo-García
SLSoledad López-Enríquez
Soledad López-Enríquez
MBM. Blanca
M. Blanca

1 August 2022 in Seminars in Cancer Biology
Verified
Journal Article
Open access
JOJavier Oliver
Javier Oliver
MGMarilina García-Aranda
Marilina García-Aranda
PCPatricia Pilar Chaves-Guerrero
Patricia Pilar Chaves-Guerrero
EAEmilio Alba
Emilio Alba
MCManuel Cobo-Dols
Manuel Cobo-Dols
Isabel BarraganIsabel Barragan
Isabel Barragan
Cancer is the second leading cause of death worldwide being responsible for 9.6 million deaths in 2018. Epigenetic alterations are key in directing the aberrant expression of tumor-associated genes that drive cellular malignant transformation and cancer progression. Among epigenetic alterations, DNA methylation is the most deeply studied one in relation to environmental exposure. Tissue biopsies have traditionally been the main procedure by which a small sample of body tissue is excised to confirm cancer diagnosis or to indicate the primary site when cancer has spread. In contrast, the analysis of circulating tumor-derived material, or tumor circulome, by means of liquid biopsy of peripheral blood, urine, saliva or sputum is a noninvasive, fast and reproducible alternative to tissue biopsy. Recently, the assessment of epigenetic alterations such as DNA methylation and hydroxymethylation in circulating free DNA has been proved possible. These marks can be associated to prognosis and response to a variety of treatments including chemotherapy, hormonotherapy or immunotherapy. Epigenetic biomarkers may offer some advantages over RNA or genetic biomarkers given their stability in bodily fluids and their high tissue-specificity. While many challenges are still ahead, the unique advantages of these types of biomarkers is urging the scientific community to persevere in their clinical validation and integration into reliable prediction models. This review aims at recapitulating the emerging noninvasive DNA methylated biomarkers of importance for prediction of prognosis and drug response in cancer.

13 March 2008 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
MTMaría J Torres
María J Torres
CMCristobalina Mayorga
Cristobalina Mayorga
JCJosé Antonio Cornejo-García
José Antonio Cornejo-García
SLSoledad López-Enríquez
Soledad López-Enríquez
PCPatricia Pilar Chaves-Guerrero
Patricia Pilar Chaves-Guerrero
MBM. Blanca
M. Blanca
Summary: Non-immediate reactions to iodine contrast media (ICM) affect 2–5% of patients receiving these agents. We studied the immunological mechanisms involved in patients with a confirmed non-immediate reaction, maculopapular exanthema, after administration of ICM. The diagnosis was carried out by skin testing or drug provocation test. The immunological study was performed in sequential peripheral blood mononuclear cells taken from the onset of the reaction by flow cytometry and in skin biopsy by immunohistochemistry, with specific recognition by the lymphocyte transformation test (LTT) with different ICM. Flow cytometry showed an increase in the different activation markers [CD69, CD25 and human leucocyte antigen D-related (HLA-DR)] and the skin homing receptor [cutaneous lymphocyte-associated antigen (CLA)] in CD4 lymphocytes, whereas perforin was higher in the CD8 lymphocytes. The skin biopsy showed a perivascular mononuclear infiltrate composed of CD4 lymphocytes, expressing CD25, HLA-DR and CLA, with eosinophils. Intradermal skin tests and the LTT were positive to several ICM, including the culprit agent in four and three patients, respectively, with negative results in all 10 tolerant controls. We showed that a specific immunological mechanism was implicated in patients with non-immediate reactions to ICM. Moreover, the positive results in skin tests and lymphocyte proliferation tests indicated that an important cross-reactivity exists.

25 August 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
RMRoksana Moraghebi
Roksana Moraghebi
AKAgnete Kirkeby
Agnete Kirkeby
PCPatricia Pilar Chaves-Guerrero
Patricia Pilar Chaves-Guerrero
RRRoger E. Rönn
Roger E. Rönn
ESEwa Sitnicka
Ewa Sitnicka
NWNiels-Bjarne Woods
Niels-Bjarne Woods
Mesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming. Amniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages. The average volume of term amniotic fluid collected was approximately 0.4 litres per donor, containing an average of 7 million viable mononuclear cells per litre, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential. The potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modelling, and regenerative medicine applications.

5 July 2012 in Blood
Verified
Journal Article
Open access
PDF file
YTYanjuan Tang
Yanjuan Tang
CPClaudia Peitzsch
Claudia Peitzsch
HCHojjatollah Nozad Charoudeh
Hojjatollah Nozad Charoudeh
MCMin Cheng
Min Cheng
PCPatricia Pilar Chaves-Guerrero
Patricia Pilar Chaves-Guerrero
ESEwa Sitnicka
Ewa Sitnicka
The earliest stages of natural killer (NK)–cell development are not well characterized. In this study, we investigated in different fetal hematopoietic tissues how NK-cell progenitors and their mature NK-cell progeny emerge and expand during fetal development. Here we demonstrate, for the first time, that the counterpart of adult BM Lin−CD122+NK1.1−DX5− NK-cell progenitor (NKP) emerges in the fetal liver at E13.5. After NKP expansion, immature NK cells emerge at E14.5 in the liver and E15.5 in the spleen. Thymic NK cells arise at E15.5, whereas functionally competent cytotoxic NK cells were present in the liver and spleen at E16.5 and E17.5, respectively. Fetal NKPs failed to produce B and myeloid cells but sustained combined NK- and T-lineage potential at the single-cell level. NKPs were also found in the fetal blood, spleen, and thymus. These findings show the emergence and expansion of bipotent NK/T-cell progenitor during fetal and adult lymphopoiesis, further supporting that NK/T-lineage restriction is taking place prethymically. Uncovering the earliest NK-cell developmental stages will provide important clues, helping to understand the origin of diverse NK-cell subsets, their progenitors, and key regulators.